S-nitrosocaptopril: In vitro characterization of pulmonary vascular effects in rats

British Journal of Pharmacology

Volumn 138, Issue 5, 2003, Pages 855-864

  Tsui, Debbie Y Y ^a   Gambino, Agatha ^a   Wanstall, Janet C ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Angiotensin converting enzyme inhibitors; Captopril; Nitric oxide donors; Nitroprusside; Platelet aggregation; Rat pulmonary artery; S nitrosocaptopril; S nitrosoglutathione

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; ANGIOTENSIN; ANGIOTENSIN I; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; FREE RADICAL; NITRIC OXIDE; NITROPRUSSIDE SODIUM; S NITROSOCAPTOPRIL; S NITROSOGLUTATHIONE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG STABILITY; IC 50; MALE; NONHUMAN; PRIORITY JOURNAL; PULMONARY ARTERY; PULMONARY HYPERTENSION; RAT; THROMBOCYTE AGGREGATION INHIBITION; VASODILATATION;

ANIMALS; CAPTOPRIL; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; PULMONARY ARTERY; RATS; RATS, WISTAR; VASOCONSTRICTION;

EID: 0037352294     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0705128     Document Type: Article

References (40)

1. ACKERMANN, A., FERNANDEZ-ALFONSO, M.S., SANCHEZ DE ROJAS, R., ORTEGA, T., PAUL, M. & GONZALEZ, C. (1998). Modulation of angiotensin-converting enzyme by nitric oxide. Br. J. Pharmacol., 124, 291-298.
2. - donation by S-nitrosothiols: implications for regulation of physiological functions by S-nitrosylation and acceleration of disulfide formation. Arch. Biochem. Phys., 318, 279-285.
3. COOKE, J.P., ANDON, N. & LOSCALZO, J. (1989). S-Nitrosocaptopril. II. Effects on vascular reactivity. J. Pharmacol. Exp. Ther., 249, 730-734.
4. DOGGRELL, S.A., WANSTALL, J.C. & GAMBINO, A. (1999). Functional effects of 4-aminopyridine (4-AP) on pulmonary and systemic vessels from normoxic control and hypoxic pulmonary hypertensive rats. Naunyn-Schmeideberg's Arch. Pharmacol., 360, 317-323.
5. • released from the nitroxyl anion donor Angeli's salt. Br. J. Pharmacol., 134, 521-528.
6. FEELISCH, M., KOTSONIS, P., SIEBE, J., CLEMENT, B. & SCHMIDT, H.H.H.W. (1999). The soluble guanylyl cyclase inhibitor 1H-[1,2,4]oxadiazolo[4,3,-a] quinoxalin-1-one is a nonselective heme protein inhibitor of nitric oxide synthase and other cytochrome P-450 enzymes involved in nitric oxide donor bioactivation. Mol. Pharmacol., 56, 243-253.
7. FEELISCH, M. & STAMLER, J.S. (1996). Donors of nitrogen oxides. In: Methods in Nitric Oxide Research. eds. Feelisch, M. & Stamler, J.S. pp. 71-115. Chichester: Wiley and Sons.
8. GAINE, S.P. & RUBIN, L.J. (1998). Primary pulmonary hypertension. The Lancet, 352, 719-725.
9. GASCO, A., FRUTTERO, R. & SORBA, G. (1996). NO-donors: an emerging class of compounds in medicinal chemistry. Il Farmaco, 51, 617-635.
10. HOMER, K.L., FIORE, S.A. & WANSTALL, J.C. (1999). Inhibition by 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ) of responses to nitric oxide-donors in rat pulmonary artery: influence of the mechanism of nitric oxide generation. J. Pharm. Pharmacol., 51, 135-139.
11. HOMER, K.L. & WANSTALL, J.C. (2000). Cyclic GMP-independent relaxation of rat pulmonary artery by spermine NONOate, a diazeniumdiolate nitric oxide donor. Br. J. Pharmacol., 131, 673-682.
12. IWAMOTO, Y., SONG, K., TAKAI, S., YAMADA, M., JIN, D., SAKAGUCHI, M., UEDA, H., KATSUOKA, Y. & MIYAZAKI, M. (2001). Multiple pathways of angiotensin I conversion and their functional role in the canine penile corpus cavernosum. J. Pharmacol. Exp. Ther., 298, 43-48.
13. JEFFERY, T.K. & WANSTALL, J.C. (1999). Perindopril, an angiotensin converting enzyme inhibitor, in pulmo + nary hypertensive rats: comparative effects on pulmonary vascular structure and function. Br. J. Pharmacol., 128, 1407-1418.
14. JEFFERY, T.K. & WANSTALL, J.C. (2001). Pulmonary vascular remodelling: a target for therapeutic intervention in pulmonary hypertension. Pharmacol. Therap., 92, 1-20.
15. JIA, L., YOUNG, X. & GUO, W. (1999). Physicochemistry, pharmacokinetics, and pharmacodynamics of S-nitrosocaptopril crystals, a new nitric oxide donor. J. Pharm. Sci., 88, 981-986.
16. LEACH, R.M., TWORT, C.H.C., CAMERON, I.R. & WARD, J.P. (1992). A comparison of the pharmacological and mechanical properties in vitro of large and small pulmonary arteries of the rat. Clin. Sci., 82, 55-62.
17. LI, C.G. & RAND, M.J. (1993). Effects of hydroxocobalamin and haemoglobin on NO-mediated relaxations in the rat anococcygeus muscle. Clin. Exp. Pharmacol. Physiol., 20, 633-640.
18. LOSCALZO, J., SMICK, D., ANDON, N. & COOKE, J. (1989). S-Nitrosocaptopril. I. Molecular characterization and effects on the vasculature and on platelets. J. Pharmacol. Exp. Ther., 249, 726-729.
19. MACKANESS, G.B. (1985). The future of angiotensin-converting enzyme inhibitors. J. Cardiovasc. Pharmacol., 7 (Suppl 1), S30-S34.
20. MARCZIN, N., RYAN, U.S. & CATRAVAS, J.D. (1992). Methylene blue inhibits nitrovasodilator- and endothelium-derived relaxing factor-induced cyclic GMP accumulation in cultured pulmonary arterial smooth muscle cells via generation of superoxide anion. J. Pharmacol. Exp. Ther., 263, 170-179.
21. MATHEWS, W.R. & KERR, S.W. (1993). Biological activity of S-nitrosothiols: the role of nitric oxide. J. Pharmacol. Exp. Ther., 267, 1529-1537.
22. MCLAUGHLIN, V.V. (2002). Medical management of primary pulmonary hypertension. Expert. Opin. Pharmacother., 3, 159-165.
23. MORRELL, N.W., MORRIS, K.G. & STENMARK, K.R. (1995). Role of angiotensin-converting enzyme and angiotensin II in development of hypoxic pulmonary hypertension. Am. J. Physiol., 269, H1186-H1194.
24. NAKAE, I., TAKAHASHI, M., KINOSHITA, T., MATSUMOTO, T. & KINOSHITA, M. (1995). The effects of S-nitrosocaptopril on canine coronary circulation. J. Pharmacol. Exp. Ther., 274, 40-46.
25. PERSSON, K., WHISS, P.A., NYHLEN, K., JACOBSSON-STRIER, M., GLINDELL, M. & ANDERSSON, R.G.G. (2000). Nitric oxide donors and angiotensin-converting enzyme inhibitors act in concert to inhibit human angiotensin-converting enzyme activity and platelet aggregation in vitro. Eur. J. Pharmacol., 406, 15-23.
26. PRAMAR, Y., DAS GUPTA, V & BETHEA, C. (1992). Stability of captopril in some aqueous systems. J. Clin. Pharm. Ther., 17, 185-189.
27. RAND, M.J. & LI, C.G. (1993). Differential effects of hydroxocobalamin on relaxations induced by nitrosothiols in rat aorta and anococcygeus muscle. Eur. J. Pharmacol., 241, 249-254.
28. RICHARD, V., HUREL-MERLE, S., SCALBERT, E., FERRY, G., LALLEMAND, F., BESSOU, J.P. & THUILLEZ, C. (2001). Functional evidence for a role of vascular chymase in the production of angiotensin II in isolated human arteries. Circulation, 104, 750-752.
29. SCHRAMMEL, A., BEHRENDS, S., SCHMIDT, K., KOESLING, D. & MAYER, B. (1996). Characterization of 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one as a heme-site inhibitor of nitric oxide-sensitive guanylyl cyclase. Mol. Pharmacol., 50, 1-5.
30. SHAFFER, J.E., LEE, F., THOMSON, S., HAN, B.J., COOKE, J.P. & LOSCALZO, J. (1991). The hemodynamic effects of S-nitrosocaptopril in anesthetized dogs. J. Pharmacol. Exp. Ther., 256, 704-709.
31. SINGH, R.J., HOGG, N., JOSEPH, J. & KALYANARAMAN, B. (1996). Mechanism of nitric oxide release from S-nitrosothiols. J. Biol. Chem., 271, 18596-18603.
32. SOGO, N., CAMPANELLA, C., WEBB, D.J. & MEGSON, I.L. (2000a). S-Nitrosothiols cause prolonged, nitric oxide-mediated relaxation in human saphenous vein and internal mammary artery: therapeutic potential in bypass surgery. Br. J. Pharmacol., 131, 1236-1244.
33. SOGO, N., MAGID, K.S., SHAW, C.A., WEBB, D.J. & MEGSON, I.L. (2000b). Inhibition of human platelet aggregation by nitric oxide donor drugs: relative contribution of cGMP-independent mechanisms. Biochem. Biophys. Res. Commun., 279, 412-419.
34. TIMMINS, P., JACKSON, I.M. & WANG, Y.J. (1982). Factors affecting captopril stability in aqueous solution. Int. J. Pharmaceut., 11, 329-336.
35. TSENG, C.-M.L., TABRIZI-FARD, M.A. & FUNG, H.-L. (2000). Differential sensitivity among nitric oxide donors toward ODQ-mediated inhibition of vascular relaxation. J. Pharmacol. Exp. Ther., 292, 737-742.
36. TSUI, D. & WANSTALL, J.C. (2001). S-Nitrosocaptopril: Effects on pulmonary artery and platelets in normal rats and pulmonary artery pressure in pulmonary hypertensive rats. Proc. Aust. Soc. Clin. Exp. Pharmacol. Toxicol., 9, 63 (Abstract).
37. WANSTALL, J.C. & JEFFERY, T.K. (1998). Recognition and management of pulmonary hypertension. Drugs, 56, 989-1007.
38. WANSTALL, J.C., JEFFERY, T.K., GAMBINO, A., LOVREN, F. & TRIGGLE, C.R. (2001). Vascular smooth muscle relaxation mediated by nitric oxide donors: a comparison with acetylcholine, nitric oxide and nitroxyl ion. Br. J. Pharmacol., 134, 463-472.
39. WANSTALL, J.C. & O'DONNELL, S.R. (1990). Endothelin and 5-hydroxytryptamine on rat pulmonary artery in pulmonary hypertension. Eur. J. Pharmacol., 176, 159-168.
40. WOLIN, M.S., CHERRY, P.D., RODENBURG, J.M., MESSINA, E.J. & KALEY, G. (1990). Methylene blue inhibits vasodilation of skeletal muscle arterioles to acetylcholine and nitric oxide via the extracellular generation of superoxide anion. J. Pharmacol. Exp. Ther., 254, 872-876.